{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
beta carotene
to a specific field?
Status:
Investigational
Source:
INN:peliglitazar [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Peliglitazar (also known as BMS 426707-01), a dual α/γ peroxisome proliferator-activated receptor agonist, has been studied in phase I/II clinical trial in patients with type 2 diabetes mellitus. However, this study was discontinued.
Status:
Investigational
Source:
INN:ertiprotafib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ertiprotafib was originally developed as an inhibitor of PTP1B. Multiple targets of ertiprotafib, in addition to PTP1B inhibition, have been suggested including dual PPARalpha/PPARgamma agonism and IKK-beta inhibition. It normalized the plasma glucose and insulin levels in diabetic animal models and progressed to a phase II clinical trial for the treatment of Type 2 diabetes mellitus. Ertiprotafib development has been discontinued.
Status:
Investigational
Source:
INN:cyclobutoic acid [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Cyclobutoic acid is a synthetic analog of mevalonic acid, developed by the Italian company Farmitalia Carlo Erba SPA. The compound inhibited the incorporation of [14C] into CO2, fatty acids and cholesterol, and was used for the treatment of hepatic deficiency.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Altinicline (SIB-1508Y, SIB-1765F) is a drug which acts as an agonist at neural nicotinic acetylcholine receptors with high selectivity for the α4β2 subtype. It stimulates release of dopamine and acetylcholine in the brain in both rodent and primate models, and progressed as far as Phase II clinical trials for Parkinson's disease, where "no antiparkinsonian or cognitive-enhancing effects were demonstrated", although its current status is unclear.
Status:
Investigational
Source:
NCT00625664: Phase 3 Interventional Completed Urinary Bladder Neoplasms
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
LAROTAXEL is a taxoid with potential antineoplastic activity. It prevents microtubule depolymerization, thereby inhibiting cell proliferation. It displays a broad spectrum of antitumor activity in vitro and in vivo, including activity against P-glycoprotein expressing tumors. LAROTAXEL was in phase III clinical trials for the treatment of breast cancer, pancreatic cancer, and bladder cancer. However, its development was discontinued.
Status:
Investigational
Source:
INN:sitogluside [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
SITOGLUSIDE (Daucosterol) inhibits cancer cell proliferation by inducing autophagy through reactive oxygen species-dependent manner. It also perturbs cell cycle and induces apoptotic cell death in A549 cells. Daucosterol has being shown to promote the proliferation of neural stem cells. Daucosterol also protects neurons against oxygen-glucose deprivation/reperfusion-mediated injury by activating IGF1 signaling pathway. Daucosterol could be potentially developed as a medicine for ischemic stroke treatment.
Class (Stereo):
CHEMICAL (RACEMIC)
Pirepolol is the beta-adrenergic blocking agent. It was developed as an antihypertensive agent.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Halocortolone, a synthetic glucocorticoid that was used as a vasoconstrictor, but was never marketed
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Ronactolol is an aminopropanol derivative and a beta-adrenergic receptor antagonist. This compound has been withdrawn from development.
Status:
Investigational
Source:
NCT02511197: Early Phase 1 Interventional Unknown status Pulmonary Fibrosis, Unspecified
(2015)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
